Medtronic plc (NYSE:MDT) finished Thursday with an addition of $1.51 to close at $77.81, an upside of 1.98 percent. An average of 5,527,180 shares of common stock have been traded in the last five days. There was a gain of $0.65 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 7,693,085 shares traded, while the 50-day average volume stands at 7,554,784.
MDT stock has increased by 1.74% in the last month. The company shares reached their 1-month lowest point of $75.76 on 12/16/22. With the stock rallying to its 52-week high on 04/21/22, shares of the company touched a low of $75.76 and a high of $114.31 in 52 weeks. It has reached a new high 12 times so far this year and lost -24.78% or -$25.64 in price. In spite of this, the price is down -31.93% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
MDT stock investors should be aware that Medtronic plc (MDT) stock had its last reported insider trading activity 17 days ago on Dec 13. In this transaction, the insider spent $1,338,736. EVP and Pres. Global Regions, TEN HOEDT ROB, disposed of 2,404 shares at a price of $81.54 on Oct 14. The insider now owns more than $196,015 worth of shares. Prior to that, EVP & Chief Financial Officer PARKHILL KAREN L went on to Sale 682 shares at $110.00 each on Mar 18. An amount of $75,020 was transacted.
Medtronic plc (MDT) has a trailing price-to-earnings (P/E) ratio of 24.16. The stock’s beta is 0.73. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.34, the price-to-book (PB) ratio at 1.99, and the price-to-cash flow ratio at 77.75.
The company has a payout ratio of 81.00%. The company’s most recent quarterly dividend payment was $0.68 a share, without any change from last year. Its latest increase dividend $0.05 reported on Wednesday May 25 2022.
The quick ratio of Medtronic plc for the three months ended July 30 was 1.40, and the current ratio was 1.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.40 and a total debt to equity ratio of 0.51 for the quarter ending July 30. Its gross profit as reported stood at $21.54 billion compared to revenue of $31.69 billion.
For the three-month period that ended July 30, Medtronic plc had $6.6 billion in cash and short-term investments compared to $20.75 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $427.0 million in the quarter, while revenues were shrunk -207.03%. The analyst consensus anticipated Medtronic plc’s latest quarter earnings to come in at $1.12 per share, but it turned out to be $1.13, a 0.90% surprise. For the quarter, EBITDA amounted to $2.07 billion. Shareholders own equity worth $1.33 billion.
From a technical analysis perspective, let’s take a brief look at Medtronic plc (MDT) price momentum. RSI 9-day as of the close on 29 December was 49.89%, suggesting the stock is Neutral, with historical volatility in this time frame at 16.50%.
As of today, MDT’s price is $77.28 +0.84% or $0.65 from its 5-day moving average. MDT is currently trading -1.56% lower than its 20-day SMA and -16.85% lower than its 100-day SMA. However, the stock’s current price level is -7.48% below the SMA50 and -26.18% below the SMA200.
The stochastic %K and %D were 27.12% and 28.30%, respectively, and the average true range (ATR) was 1.65. With the 14-day stochastic at 37.35% and the average true range at 1.73, the RSI (14) stands at 47.05%. The stock has reached 0.13 on the 9-day MACD Oscillator while the 14-day reading was at -0.54.
Oppenheimer downgraded Medtronic plc (NYSE: MDT) to a a Perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Medtronic plc (MDT) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell MDT, while 16 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 11 others rate it as a “buy”.
What is MDT’s price target for the next 12 months?
Analysts predict a range of price targets between $77.00 and $127.00, with a median target of $85.00. Taking a look at these predictions, the average price target given by analysts for Medtronic plc (MDT) stock is $88.86.